A detailed history of First Affirmative Financial Network transactions in Abb Vie Inc. stock. As of the latest transaction made, First Affirmative Financial Network holds 4,771 shares of ABBV stock, worth $858,780. This represents 0.53% of its overall portfolio holdings.

Number of Shares
4,771
Previous 4,502 5.98%
Holding current value
$858,780
Previous $772,000 22.02%
% of portfolio
0.53%
Previous 0.54%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$163.84 - $199.33 $44,072 - $53,619
269 Added 5.98%
4,771 $942,000
Q2 2024

Jul 10, 2024

BUY
$154.79 - $180.76 $94,112 - $109,902
608 Added 15.61%
4,502 $772,000
Q1 2024

Apr 11, 2024

SELL
$159.82 - $182.1 $3,516 - $4,006
-22 Reduced 0.56%
3,894 $709,000
Q4 2023

Jan 08, 2024

BUY
$137.6 - $154.97 $85,587 - $96,391
622 Added 18.88%
3,916 $606,000
Q3 2023

Oct 16, 2023

BUY
$133.59 - $154.65 $25,114 - $29,074
188 Added 6.05%
3,294 $491,000
Q2 2023

Jul 10, 2023

BUY
$132.51 - $164.9 $62,544 - $77,832
472 Added 17.92%
3,106 $418,000
Q1 2023

Apr 11, 2023

BUY
$144.61 - $166.54 $8,676 - $9,992
60 Added 2.33%
2,634 $419,000
Q4 2022

Jan 23, 2023

BUY
$138.31 - $165.87 $6,500 - $7,795
47 Added 1.86%
2,574 $0
Q3 2022

Oct 20, 2022

BUY
$134.21 - $153.93 $25,365 - $29,092
189 Added 8.08%
2,527 $339,000
Q2 2022

Jul 13, 2022

BUY
$137.62 - $174.96 $15,138 - $19,245
110 Added 4.94%
2,338 $358,000
Q1 2022

Apr 12, 2022

SELL
$131.98 - $163.75 $93,177 - $115,607
-706 Reduced 24.06%
2,228 $361,000
Q4 2021

Feb 15, 2022

BUY
$107.43 - $135.93 $4,619 - $5,844
43 Added 1.49%
2,934 $397,000
Q3 2021

Oct 26, 2021

BUY
$106.4 - $120.78 $307,602 - $349,174
2,891 New
2,891 $312,000

Others Institutions Holding ABBV

About AbbVie Inc.


  • Ticker ABBV
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 1,768,099,968
  • Market Cap $318B
  • Description
  • AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...
More about ABBV
Track This Portfolio

Track First Affirmative Financial Network Portfolio

Follow First Affirmative Financial Network and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Affirmative Financial Network, based on Form 13F filings with the SEC.

News

Stay updated on First Affirmative Financial Network with notifications on news.